Emergent BioSolutions (EBS) Tops Q4 EPS by 48c, Revenues Beat; Offers FY21 Revenue Guidance Above Consensus

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 6/24/2026

1. SPCX
2. FDX
3. META
4. ABBV
5. SPY
6. ACN
7. BLZE
8. IBM
9. NKE
10. MU

Go back to Emergent BioSolutions (EBS) Tops Q4 EPS by 48c, Revenues Beat; Offers FY21 Revenue Guidance Above Consensus

Emergent BioSolutions (EBS) PT Raised to $130 at Cantor Fitzgerald Following EPS

February 19, 2021 7:39 AM EST

Cantor Fitzgerald analyst Brandon Folkes raised the price target on Emergent BioSolutions (NYSE: EBS) to $130.00 (from $110.00) while maintaining an Overweight rating.

The analyst commented, "Post 4Q20, we reiterate our Overweight rating and raise our 12-month price target to $130, from $110. EBS continues to be... More